<DOC>
	<DOCNO>NCT01032122</DOCNO>
	<brief_summary>The purpose study determine whether rituximab adjuvant therapy clinical stage IIIc / IV ( evidence disease , AJCC ( American Joint Committee Cancer ) 2002 ) melanoma patient safe prolongs overall survival disease-free interval .</brief_summary>
	<brief_title>Rituximab Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Histologically verify nonocular melanoma stage IIIc/IV , evidence disease ECOG ( Eastern Cooperative Oncology Group ) performance status &gt; 2 Ocular melanoma Immunodeficiency syndromes hypogammaglobulinaemia Active autoimmune disease Treatment immunosuppressive agent steroid Depressed bone marrow function ( Leukopenia &lt; 3000 , platelet count &lt; 100.000 ) Cardiac insufficiency NYHA ( New York Heart Association ) IV active Hepatitis B , C , HIV infection Pregnancy lactation Interstitial pulmonary disease Former treatment antiCD20 antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>melanoma</keyword>
	<keyword>rituximab</keyword>
	<keyword>metastatic</keyword>
	<keyword>stage IIIc/IV</keyword>
	<keyword>stem cell</keyword>
	<keyword>overall survival</keyword>
	<keyword>disease free interval</keyword>
	<keyword>anti-CD20 therapy</keyword>
</DOC>